Co-Authors
This is a "connection" page, showing publications co-authored by Annalisa Ruggeri and Paolo Scarpellini.
Connection Strength
0.616
-
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 06; 76:43-49.
Score: 0.110
-
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol. 2021 Apr; 3(4):e253-e261.
Score: 0.058
-
Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. J Cardiothorac Vasc Anesth. 2021 Dec; 35(12):3631-3641.
Score: 0.058
-
Biobanking for COVID-19 research. Panminerva Med. 2020 Oct 19.
Score: 0.057
-
Integrated clinical role of echocardiography in patients with COVID-19. Heart. 2020 12; 106(23):1864-1865.
Score: 0.057
-
Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020 09; 106(17):1324-1331.
Score: 0.056
-
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e465-e473.
Score: 0.055
-
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020 08; 217:108509.
Score: 0.055
-
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020 Jun; 2(6):e325-e331.
Score: 0.055
-
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency Crit Care Resusc. 2020 04 01; 22(2):91-94.
Score: 0.055